Acumen Pharmaceuticals announced an extension of its collaboration with Lonza, focusing on drug product manufacturing for sabirnetug (ACU193). This agreement builds upon a previous successful collaboration for drug substance manufacturing. The extension aims to secure manufacturing services for both clinical and potential commercial supply of sabirnetug.
The drug product manufacturing will take place at Lonza’s Visp, Switzerland site. This strategic move is essential for ensuring the scalability and availability of sabirnetug as it progresses through clinical development. Securing manufacturing capabilities early is a critical step towards potential market entry.
This expanded partnership underscores Acumen's commitment to advancing sabirnetug, its lead candidate for early Alzheimer's disease. Reliable manufacturing is a key component of de-risking the development pathway and preparing for potential future commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.